Market closed · data as of 27 Aug 2026 · source NSE via Alphave. Open the live chart →
Gland Pharma is a Hyderabad-based injectables manufacturer operating mainly a B2B model — developing and producing sterile injectables (vials, ampoules, pre-filled syringes, lyophilised products) for partners who market them in the US and other regulated markets. It has strength in heparin and complex injectables, holds a large ANDA portfolio with partners, and acquired France's Cenexi to add CDMO capabilities. China's Fosun Pharma is the promoter.
One of India's largest injectable-focused pharma companies with a predominantly US-regulated-market business.
Gland Pharma Ltd. is a constituent of NIFTY 500, NIFTY PHARMA, NIFTY SMALLCAP 100, NIFTY SMALLCAP 250, NIFTY SMALLCAP 50. See where it sits on the market heatmap →
Consolidated annual figures taken from Gland Pharma Ltd.'s own filed statements — not estimates, and not restated by us. The most recent period shown is FY26 (year ended 31 Mar 2026).
| Metric | FY26 | FY25 | FY24 |
|---|---|---|---|
| EPS (basic, ₹) | 62.35 | 42.40 | 46.90 |
| Book value / share (₹) | 628.67 | 555.40 | 529.65 |
| Return on equity | 9.9% | 7.6% | 8.8% |
| Return on capital employed | 11.1% | 9.2% | 10.7% |
| Operating margin | 18.8% | 15.9% | 17.4% |
| Net margin | 16.0% | 12.4% | 13.6% |
| EBITDA | ₹1,630 Cr | ₹1,269 Cr | ₹1,333 Cr |
| Free cash flow | ₹537 Cr | ₹521 Cr | ₹599 Cr |
| Total debt | ₹243 Cr | ₹269 Cr | ₹320 Cr |
| Debt to equity | 0.02 | 0.03 | 0.04 |
| Interest coverage | 36.2 | 21.2 | 37.7 |
| Current ratio | 4.68 | 4.33 | 4.04 |
| Shares outstanding | 16,47,60,000 | 16,47,60,000 | 16,47,10,000 |
Open the full income statement, balance sheet and cash flow for GLAND →
As disclosed for the quarter ended 30 Jun 2026.
Institutional ownership changes quarter to quarter. See daily FII and DII flows across the market →
Companies Alphave classifies in the same sub-sector, closest by market capitalisation.